Clinical Trials

Enrolling Trials

101-110  of  165
DTL-CIRB-Randomized Phase III Trial of Perioperative Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Miscellaneous Neoplasm
Adult
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
DTL - CIRB, RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Lung
Adult
Testing multiple Fiscal Activity Codes for Financial Reporting
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB-Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Lung
Adult
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Standard chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, pemetrexed, and etoposide. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding SBRT to the standard treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with inoperable non-small cell lung cancer than giving the standard treatment alone.
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
Advarra, ICH, CORRECT- MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease
Gastro-Intestinal (GI)
Adult
Objective/Abstract
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
Testing.
testing
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ORCA: TEST - Replace Calendar
Knecht, Justin E
Testing: copy, update, and replace calendar
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ORCA: TEST - Hide Caledar Event
Knecht, Justin E
Hiding a Calendar event; effect on Milestones
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Velos - Multiple Fiscal Activity
Knecht, Justin E
Testing multiple Fiscal Activity Codes for Financial Reporting
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Calendar Access
Knecht, Justin E
Testing Calendar Access
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Financial Demo 1
Knecht, Justin E
Demonstrate ability to capture and report financial activities in Velos
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449